PRODUCT
ESSA Pharma Terminates Masofaniten Development After Phase 2 Trial Failure in Prostate Cancer
ESSA Pharma, Masofaniten, Prostate Cancer, Phase 2 Trial, Enzalutamide, Xtandi, Clinical Trial Termination
European Commission Imposes €463 Million Fine on Teva for Anti-Competitive Practices in MS Drug Market
Teva, European Commission, fine, MS drug, competition tactics, Copaxone, market dominance
Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts
Amgen, Obesity Therapies, Pipeline Cuts, Strategic Refocus, MariTide, Phase 3 Program
Iambic Therapeutics Enhances AI Suite with “Enchant” for Predictive Preclinical Drug Development
Iambic Therapeutics, AI, Enchant, preclinical predictive powers, drug discovery, clinical success prediction
Roche Revisits Dyno for AAV Technology with $50M Upfront Payment
Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership
Starboard Value Targets Kenvue for Revitalization Following $1B Stake in Pfizer
Starboard Value, Kenvue, Johnson & Johnson, Pfizer, activist investor, consumer health, pharmaceuticals
Seaport Therapeutics Secures $225M Series B Funding to Revolutionize Neuropsychiatric Medicines
Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, clinical-stage pipeline, major depressive disorder, generalized anxiety disorder.
Seaport Therapeutics Secures $225 Million in Oversubscribed Series B Funding
Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, biotech investment
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Standalone Influenza Vaccine Trials
Novavax, FDA, Clinical Hold, COVID-19, Influenza, Vaccine Trials, Motor Neuropathy
Johnson & Johnson’s Oncology Segment Thrives with Darzalex and Carvykti, Offsetting Stelara Decline
Johnson & Johnson, Darzalex, Carvykti, Stelara, Oncology, Multiple Myeloma, Pharmaceutical Sales